These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25674793)

  • 1. Abacavir-reactive memory T cells are present in drug naïve individuals.
    Lucas A; Lucas M; Strhyn A; Keane NM; McKinnon E; Pavlos R; Moran EM; Meyer-Pannwitt V; Gaudieri S; D'Orsogna L; Kalams S; Ostrov DA; Buus S; Peters B; Mallal S; Phillips E
    PLoS One; 2015; 10(2):e0117160. PubMed ID: 25674793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
    Small CB; Margolis DA; Shaefer MS; Ross LL
    BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of abacavir hypersensitivity by ELISpot method.
    Esser S; Jablonka R; Heinemann FM; Reuter S; Jaeger H; von Krosigk A; Schenk-Westkamp P; Schadendorf D; Horn PA; Lindemann M
    Inflamm Allergy Drug Targets; 2012 Jun; 11(3):227-34. PubMed ID: 22338581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients.
    Faridi RM; Patel S; Dharmani-Khan P; Gill J; Berka N; Khan FM
    Microbiol Immunol; 2020 Mar; 64(3):210-218. PubMed ID: 31876322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced alloreactivity: A new paradigm for allorecognition.
    D'Orsogna LJ; Almeida CM; van Miert P; Zoet YM; Anholts JDH; Chopra A; Watson M; Witt C; John M; Claas FHJ
    Am J Transplant; 2019 Sep; 19(9):2606-2613. PubMed ID: 31125485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity.
    Schnyder B; Adam J; Rauch A; Thurnheer MC; Pichler WJ
    J Allergy Clin Immunol; 2013 Sep; 132(3):756-758. PubMed ID: 23706613
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
    Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
    Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.
    Naisbitt DJ; Yang EL; Alhaidari M; Berry NG; Lawrenson AS; Farrell J; Martin P; Strebel K; Owen A; Pye M; French NS; Clarke SE; O'Neill PM; Park BK
    AIDS; 2015 Nov; 29(18):2385-95. PubMed ID: 26372480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avidity determines T-cell reactivity in abacavir hypersensitivity.
    Adam J; Eriksson KK; Schnyder B; Fontana S; Pichler WJ; Yerly D
    Eur J Immunol; 2012 Jul; 42(7):1706-16. PubMed ID: 22585534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.